TABLE 2.

Clinical/cognitive/biomarker outcomes of participants at baseline and at visits closest to dose escalation

	Baseline a			Visit closest to dose escalation b
Outcomes	GantenerumabN = 52	SolanezumabN = 50	SharedplaceboN = 40	GantenerumabN = 47	SolanezumabN = 37	SharedplaceboN = 34
CDR c  0 CDR 0.5 CDR = 1 CDR > 1 N (%)	31 (60) 15 (29) 6 (12) 0 (0)	30 (60) 13 (26) 7 (14) 0 (0)	22 (55) 15 (38) 3 (8) 0 (0)	26 (55) 13 (28) 5 (11) 3 (6)	22 (59) 8 (22) 2 (5) 5 (14)	18 (55) 7 (21) 6 (18) 2 (6)
Digit Symbol d	46.96 ± 20.56	46.06 ± 19.94	46.63 ± 19.12	48.13 ± 23.83	50.69 ± 23.34	54.74 ± 21.64
MMSE e	27.10 ± 3.45	26.72 ± 4.11	26.68 ± 3.97	25.91 ± 5.52	26.06 ± 6.45	25.70 ± 6.17
Logical Memory f	9.90 ± 6.33	9.86 ± 6.86	9.40 ± 6.45	11.55 ± 7.37	13.38 ± 7.96	12.12 ± 7.59
ISLT g	5.96 ± 4.04	6.56 ± 3.95	5.80 ± 4.42	6.13 ± 4.55	5.67 ± 4.26	6.24 ± 4.70
CDR‐SB h	1.33 ± 2.08	1.37 ± 2.01	1.43 ± 1.87	2.13 ± 3.13	2.61 ± 4.46	2.30 ± 3.39
PiB‐PET composite SUVR	2.64 ± 1.23	2.75 ± 1.32	2.62 ± 1.20	2.63 ± 1.25	2.76 ± 1.29	2.58 ± 1.14

Note: Plus‐minus values are means ± SD. PiB‐PET composite SUVR refers to brain amyloid burden measured by the average SUVR of cortical regions of interest (superior frontal, rostral middle frontal, superior temporal, middle temporal, lateral orbito‐frontal, medial orbito‐frontal and precuneus), assessed by PiB‐PET.

^a Fifty‐two participants were randomized to the solanezumab arm; two did not have post‐baseline data and were excluded from the modified intent‐to‐treat population.

^b Because the clinical and cognitive assessments were administered annually or every 6 months, the timing of these assessments did not match the starting time of dose escalation, for example, participants started dose escalation in between two visits.

^c CDR scores range from 0 to 3, with higher scores indicating worse cognition and daily function.

^d Digit Symbol Substitution Test (Digit Symbol) scores range from 0 to 93, with lower scores indicating poorer cognitive performance.

^e MMSE scores range from 0 to 30, with lower scores indicating poorer cognitive performance.

^f Logical Memory Delayed Recall Test (Logical Memory) scores range from 0 to 25, with lower scores indicating poorer cognitive performance.

^g ISLT scores range from 0 to 12, with lower scores indicating poorer cognitive performance.

^h CDR‐SB scores range from 0 to 18, with higher scores indicating worse cognition and daily function.

Abbreviations: CDR, Clinical Dementia Rating Scale; CDR‐SB, Clinical Dementia Rating Sum of Boxes; ISLT, International Shopping List Test‐Delayed Recall; MMSE, Mini‐Mental State Examination; PiB‐PET, positron emission tomography with Pittsburgh compound B; SD, standard deviation; SUVR, standardized uptake value ratio.